Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Other Operating Expenses (2016 - 2024)

PharmaCyte Biotech (PMCB) has disclosed Other Operating Expenses for 15 consecutive years, with -$1.2 million as the latest value for Q2 2024.

  • Quarterly Other Operating Expenses fell 337.21% to -$1.2 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was -$1.2 million through Jan 2025, down 131.8% year-over-year, with the annual reading at -$1.6 million for FY2024, N/A changed from the prior year.
  • Other Operating Expenses for Q2 2024 was -$1.2 million at PharmaCyte Biotech, down from $1.5 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $2.0 million in Q4 2022, with the low at -$1.2 million in Q2 2024.
  • Average Other Operating Expenses over 5 years is $714042.9, with a median of $606377.0 recorded in 2020.
  • The sharpest move saw Other Operating Expenses soared 220.42% in 2022, then tumbled 337.21% in 2024.
  • Over 5 years, Other Operating Expenses stood at $710191.0 in 2020, then fell by 13.97% to $610948.0 in 2021, then skyrocketed by 220.42% to $2.0 million in 2022, then plummeted by 46.11% to $1.1 million in 2023, then plummeted by 210.02% to -$1.2 million in 2024.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at -$1.2 million, $1.5 million, and $1.1 million for Q2 2024, Q1 2024, and Q4 2023 respectively.